NYSE:CTLT

Catalent Competitors

$109.36
+0.73 (+0.67 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$107.17
Now: $109.36
$109.72
50-Day Range
$101.51
MA: $106.67
$116.40
52-Week Range
$56.70
Now: $109.36
$127.68
Volume840,178 shs
Average Volume1.05 million shs
Market Capitalization$18.62 billion
P/E Ratio69.66
Dividend YieldN/A
Beta1.5

Competitors

Catalent (NYSE:CTLT) Vs. VRTX, REGN, TAK, ALXN, BGNE, and RPRX

Should you be buying CTLT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Catalent, including Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), and Royalty Pharma (RPRX).

Vertex Pharmaceuticals (NASDAQ:VRTX) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 97.8% of Catalent shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Catalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Vertex Pharmaceuticals and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Catalent9.25%14.20%4.83%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Catalent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Catalent01702.88

Vertex Pharmaceuticals currently has a consensus price target of $293.2083, indicating a potential upside of 33.18%. Catalent has a consensus price target of $125.1250, indicating a potential upside of 14.42%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Catalent.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Catalent's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.69$1.18 billion$4.2951.32
Catalent$3.09 billion6.02$173 million$1.8858.17

Vertex Pharmaceuticals has higher revenue and earnings than Catalent. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Catalent on 11 of the 15 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Institutional & Insider Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Catalent and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Regeneron Pharmaceuticals051412.80

Catalent currently has a consensus target price of $125.1250, indicating a potential upside of 14.42%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, indicating a potential upside of 27.71%. Given Regeneron Pharmaceuticals' higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Catalent.

Profitability

This table compares Catalent and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings and Valuation

This table compares Catalent and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.02$173 million$1.8858.17
Regeneron Pharmaceuticals$7.86 billion6.87$2.12 billion$21.4723.49

Regeneron Pharmaceuticals has higher revenue and earnings than Catalent. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Catalent on 11 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Volatility & Risk

Takeda Pharmaceutical has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Catalent9.25%14.20%4.83%

Valuation & Earnings

This table compares Takeda Pharmaceutical and Catalent's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.76$407.02 million$1.789.46
Catalent$3.09 billion6.02$173 million$1.8858.17

Takeda Pharmaceutical has higher revenue and earnings than Catalent. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Takeda Pharmaceutical and Catalent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical02002.00
Catalent01702.88

Catalent has a consensus price target of $125.1250, suggesting a potential upside of 14.42%. Given Catalent's stronger consensus rating and higher probable upside, analysts clearly believe Catalent is more favorable than Takeda Pharmaceutical.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 97.8% of Catalent shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Catalent beats Takeda Pharmaceutical on 11 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Risk and Volatility

Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Catalent and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares Catalent and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.02$173 million$1.8858.17
Alexion Pharmaceuticals$4.99 billion7.37$2.40 billion$9.7417.10

Alexion Pharmaceuticals has higher revenue and earnings than Catalent. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Catalent and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Alexion Pharmaceuticals017412.27

Catalent currently has a consensus price target of $125.1250, suggesting a potential upside of 14.42%. Alexion Pharmaceuticals has a consensus price target of $153.4286, suggesting a potential downside of 7.87%. Given Catalent's stronger consensus rating and higher probable upside, equities analysts plainly believe Catalent is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Catalent on 9 of the 15 factors compared between the two stocks.

Catalent (NYSE:CTLT) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk and Volatility

Catalent has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Insider and Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Catalent and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
BeiGene-569.22%-56.81%-39.93%

Earnings and Valuation

This table compares Catalent and BeiGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.02$173 million$1.8858.17
BeiGene$428.21 million62.69$-948,630,000.00($15.80)-18.53

Catalent has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Catalent and BeiGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
BeiGene21602.44

Catalent presently has a consensus price target of $125.1250, suggesting a potential upside of 14.42%. BeiGene has a consensus price target of $319.3750, suggesting a potential upside of 9.09%. Given Catalent's stronger consensus rating and higher probable upside, research analysts clearly believe Catalent is more favorable than BeiGene.

Summary

Catalent beats BeiGene on 12 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 2.5% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Catalent and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Royalty PharmaN/AN/AN/A

Earnings and Valuation

This table compares Catalent and Royalty Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.02$173 million$1.8858.17
Royalty PharmaN/AN/AN/AN/AN/A

Catalent has higher revenue and earnings than Royalty Pharma.

Analyst Recommendations

This is a breakdown of current recommendations for Catalent and Royalty Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Royalty Pharma05402.44

Catalent presently has a consensus price target of $125.1250, suggesting a potential upside of 14.42%. Royalty Pharma has a consensus price target of $51.8750, suggesting a potential upside of 25.18%. Given Royalty Pharma's higher probable upside, analysts clearly believe Royalty Pharma is more favorable than Catalent.

Summary

Catalent beats Royalty Pharma on 7 of the 9 factors compared between the two stocks.


Catalent Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.16+0.4%$56.98 billion$4.16 billion27.80Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$504.42+0.9%$54.04 billion$7.86 billion18.44Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.84+0.7%$53.14 billion$30.20 billion56.14Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$166.54+0.6%$36.79 billion$4.99 billion38.91News Coverage
BeiGene logo
BGNE
BeiGene
1.1$292.75+3.6%$26.85 billion$428.21 million-14.49
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.44+0.8%$25.16 billionN/A0.00Dividend Announcement
Increase in Short Interest
Genmab A/S logo
GMAB
Genmab A/S
1.4$35.74+0.4%$23.44 billion$804.57 million27.71Analyst Report
News Coverage
CureVac logo
CVAC
CureVac
0.6$110.78+2.0%$20.71 billionN/A0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.06+0.9%$20.40 billion$1.30 billion24.88
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.03+1.0%$15.96 billion$219.75 million-17.37Analyst Report
News Coverage
Gap Up
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.66+2.2%$14.50 billion$3.07 billion-53.79Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.45+0.2%$14.45 billion$1.70 billion18.18Analyst Report
News Coverage
Zai Lab logo
ZLAB
Zai Lab
1.6$150.77+9.0%$13.36 billion$12.98 million-49.76Analyst Report
News Coverage
Gap Up
Grifols logo
GRFS
Grifols
1.3$18.20+1.1%$12.51 billion$5.71 billion16.25Analyst Report
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$67.36+2.0%$11.20 billion$2.32 billion55.67Gap Down
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.11+1.7%$11.04 billion$16.89 billion-2.75Decrease in Short Interest
News Coverage
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.44+2.4%$10.36 billion$8.60 billion-5.22
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.09+0.6%$9.47 billion$2.16 billion53.03Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$207.58+1.8%$9.25 billion$1.45 billion19.64
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.49+3.4%$9.14 billionN/A0.00Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.12+2.6%$8.27 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.82+0.6%$7.89 billion$3.34 million-20.24News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$104.99+0.4%$7.03 billion$103.71 million-23.92Analyst Report
Insider Selling
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.12+1.6%$6.95 billion$87.99 million-81.10
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.40+0.1%$6.85 billion$311.33 million-126.98News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.03+2.7%$6.72 billion$14.98 million-15.23News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.16+3.0%$5.80 billion$1.12 billion85.75Analyst Report
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.30+1.4%$5.66 billion$380.83 million-9.12Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$39.96+7.1%$5.62 billion$150,000.00-18.85Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$42.05+0.8%$5.62 billion$4.84 billion-700.72Dividend Announcement
Allakos logo
ALLK
Allakos
1.7$104.13+1.0%$5.57 billionN/A-38.00
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.58+1.3%$5.44 billion$66.51 million17.08Analyst Report
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.66+1.0%$5.22 billion$1.00 billion-12.07Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$70.03+3.6%$4.90 billion$85.54 million0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$73.65+1.8%$4.57 billionN/A-6.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.45+2.2%$4.29 billion$6.87 million-7.10Analyst Report
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.00+0.3%$4.22 billion$204.89 million-36.25
I-Mab logo
IMAB
I-Mab
1.2$56.82+2.2%$4.09 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.76+2.1%$4.03 billion$806.43 million-9.46Analyst Report
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.68+2.1%$3.89 billion$117.91 million-11.29
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99+0.0%$3.70 billionN/A-6.20
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$42.34+5.1%$3.68 billionN/A0.00Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$71.54+1.6%$3.56 billionN/A-20.38
LEGN
Legend Biotech
1.2$26.72+2.6%$3.55 billion$64.39 million0.00Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.62+3.4%$3.52 billion$1.11 billion21.10High Trading Volume
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.81+0.1%$3.43 billion$114.62 million-7.58
Insmed logo
INSM
Insmed
1.2$32.30+0.2%$3.34 billion$136.47 million-12.42News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.80+0.4%$3.33 billion$339.08 million-12.09
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.31+2.7%$3.26 billion$306.98 million-6.63
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.26+2.2%$3.23 billion$26.52 million-7.86Unusual Options Activity
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.